Custom Manufacturing, Project Outsourcing, your Trusted Partner from China
The field of hematological oncology is continuously advancing, with a growing emphasis on understanding and targeting the specific molecular drivers of diseases like leukemia. Among the most impactful discoveries has been the role of epigenetic regulators, such as histone methyltransferases, in cancer development. The enzyme DOT1L (Disruptor of telomeric silencing 1-like) has emerged as a particularly promising target, especially in the context of MLL-rearranged leukemias.
The Link Between DOT1L and MLL-Rearranged Leukemia
MLL-rearranged leukemias are aggressive forms of blood cancer characterized by specific chromosomal translocations involving the MLL gene. These rearrangements lead to the production of aberrant fusion proteins that hijack normal cellular processes, driving uncontrolled cell proliferation and contributing to leukemogenesis. A key mechanism by which these fusion proteins exert their effects is through the recruitment and dysregulation of DOT1L. DOT1L, in turn, catalyzes the methylation of H3K79, an epigenetic modification that plays a critical role in maintaining the expression of oncogenic target genes, such as HOXA9 and PBX3, in these leukemic cells. Disrupting this epigenetic signature is therefore a rational therapeutic strategy.
EPZ-5676: A Leading DOT1L Inhibitor
EPZ-5676, also known as Pinometostat, is a potent and selective small molecule inhibitor designed to target DOT1L. Its mechanism of action centers on competitively inhibiting the enzyme's ability to bind S-adenosyl methionine (SAM), thereby preventing H3K79 methylation. This targeted inhibition effectively reverses the aberrant epigenetic state associated with MLL-rearranged leukemias, leading to decreased expression of leukemic oncogenes and promoting cancer cell differentiation or apoptosis. The high selectivity and demonstrated efficacy of EPZ-5676 in preclinical models, including its ability to cause complete tumor regression in animal studies, underscore its therapeutic potential and make it a critical compound for research and development.
Sourcing High-Quality EPZ-5676 for Your Research
Researchers and pharmaceutical companies worldwide are actively investigating the therapeutic applications of DOT1L inhibitors. To facilitate this vital work, access to high-quality, reliable compounds is essential. We are a leading manufacturer and supplier of pharmaceutical intermediates, including EPZ-5676 (CAS 1380288-87-8), offering products that meet rigorous purity and quality standards. When you need to purchase EPZ-5676, choosing a reputable supplier ensures the integrity of your research. We are committed to providing researchers with the tools they need to advance the understanding and treatment of MLL-rearranged leukemia. Contact us to discuss your requirements for EPZ-5676, inquire about bulk pricing, and explore how we can support your critical projects in the pharmaceutical industry.
Manufacturing Facilities
Professional Export Experience
to Global Customers
1. 20 years of R&D, manufacturing and sales experience, serving customers in 60 countries and regions around the world;
2. Own R&D laboratory, pilot platform and large-scale production workshop, which can meet the audit requirements of global customers;
3. We can satisfy customers' perfect transition from small scale lab requirements (gram level) to commercialization requirements (hundred tons level).
A: We don't have Minimum Order Quantity, exact quantity should be provided before quotation for us to calculate the exact cost.
A: We don't provide free samples due to lots of request and expensive international courier's cost, we can deduct the sample charge after commercial order placed.
A: Our payment terms: Small or sample order: T/T IN ADVANCE. Commercial order: First order should be by T/T IN ADVANCE or L/C at sight, and following orders T/T 30~90days is acceptable subject to approval of credit application.
